What is the approximate market price range for a bottle of Belumosudil tablets?

Belumosudil mesylate tablets (Belumosudil), as a kinase inhibitor used to treat chronic graft-versus-host disease (GVHD), has been marketed in China and has been included in medical insurance. However, its price has been a major concern for patients and the health insurance system. The high price of Besudil is mainly due to its research and development costs as an innovative drug and the uniqueness of its therapeutic effects. Currently, in China, the common specification of Besudil is 0.2g*30 tablets, and the market price per box is about RMB 10,000 to RMB 20,000, which is relatively high.

The price will be affected by different factors, including drug procurement channels, production costs, market demand and local exchange rates. Although Besudil has been included in medical insurance, for some patients, even with such a reimbursement ratio, the cost of the drug will still bring a large financial burden to the patients. Especially during the long-term use of the drug, the overall cost of besudil may still cause considerable pressure on families.

Compared with the pricing in the domestic market, the price of Besudil's original drug is more expensive overseas, especially in developed countries such as the United States, where the price can reach more than $10,000 per box. Such prices make patients face more severe financial challenges abroad. However, with the opening of the global drug market and the launch of generic drugs, the price of besudil may be reduced to a certain extent.

At present, generic drugs of Besudil are also available overseas. Taking the generic version produced by the Lucius Pharmaceutical Factory in Laos as an example, each box of the same specification of generic medicine is priced at about 4,000 yuan, which is relatively affordable. However, its price fluctuates greatly, and the specific selling price is affected by exchange rate fluctuations. In addition, generic drugs are usually close to the original drugs in efficacy and quality, but patients still need to pay attention to the source and quality certification of the drug when choosing to ensure the safety and therapeutic effect of the drug.

Reference materials:https://www.rezurock.com/living-with-chronic-gvhd